|
Jennifer Fitzenberger
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
An over-the-counter vitamin in high doses prevented memory loss in
mice with Alzheimer's disease, and UC Irvine scientists now are
conducting a clinical trial to determine its effect in humans.
Nicotinamide, a form of vitamin B3, lowered levels of a protein called
phosphorylated tau that leads to the development of tangles, one of two
brain lesions associated with Alzheimer's disease. The vitamin also
strengthened scaffolding along which information travels in brain
cells, helping to keep neurons alive and further preventing symptoms in
mice genetically wired to develop Alzheimer's.
"Nicotinamide has a very robust effect on neurons," said Kim Green,
UCI scientist and lead author of the study. "Nicotinamide prevents loss
of cognition in mice with Alzheimer's disease, and the beauty of it is
we already are moving forward with a clinical trial."
The study appears online Nov. 5 in the Journal of Neuroscience.
Nicotinamide is a water-soluble vitamin sold in health food stores.
It generally is safe but can be toxic in very high doses. Clinical
trials have shown it benefits people with diabetes complications and
has anti-inflammatory properties that may help people with skin
conditions.
Nicotinamide belongs to a class of compounds called HDAC inhibitors,
which have been shown to protect the central nervous system in rodent
models of Parkinson's and Huntington's diseases and amyotrophic lateral
sclerosis. Clinical trials are underway to learn whether HDAC
inhibitors help ALS and Huntington's patients.
In the nicotinamide study, Green and his colleague, Frank LaFerla,
added the vitamin to drinking water fed to mice. They tested the
rodents' short-term and long-term memory over time using water-maze and
object-recognition tasks and found that treated Alzheimer's mice
performed at the same level as normal mice, while untreated Alzheimer's
mice experienced memory loss.
The nicotinamide, in fact, slightly enhanced cognitive abilities in
normal mice. "This suggests that not only is it good for Alzheimer's
disease, but if normal people take it, some aspects of their memory
might improve," said LaFerla, UCI neurobiology and behavior professor.
Scientists also found that the nicotinamide-treated animals had
dramatically lower levels of the tau protein that leads to the
Alzheimer's tangle lesion. The vitamin did not affect levels of the
protein beta amyloid, which clumps in the brain to form plaques, the
second type of Alzheimer's lesion.
Nicotinamide, they found, led to an increase in proteins that
strengthen microtubules, the scaffolding within brain cells along which
information travels. When this scaffolding breaks down, the brain cells
can die. Neuronal death leads to dementia experienced by Alzheimer's
patients.
"Microtubules are like highways inside cells. What we're doing with
nicotinamide is making a wider, more stable highway," Green said. "In
Alzheimer's disease, this highway breaks down. We are preventing that
from happening."
Source: University of California - Irvine
Original article: Kim N. Green, Joan S. Steffan, Hilda Martinez-Coria, Xuemin Sun, Steven S. Schreiber, Leslie Michels Thompson, and Frank M. LaFerla. Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition
and Selective Reduction of Thr231-Phosphotau. The Journal of Neuroscience, 2008, 28(45):11500-11510.
|